Literature DB >> 26315707

New superior-inferior visual field asymmetry indices for detecting POAG and their agreement with the glaucoma hemifield test.

N Ghazali1, T Aslam1,2, D B Henson1,2.   

Abstract

PURPOSE: To describe and measure the discriminatory performance of three new superior-inferior asymmetry indices for detecting primary open angle glaucoma (POAG) and to compare these with the glaucoma hemifield test (GHT).
METHODS: In all, 412 control and 247 POAG eyes were selected from a visual field database of patients attending the Manchester Royal Eye Hospital. Age-adjusted defect asymmetries were calculated for each of the 22 vertically mirrored test point pairs used in the GHT. The three new indices, hemifield mean difference (HMD) and hemifield standard deviation (HSD) of the asymmetry values along with the number of test pairs (NP) falling outside the 85% probability limits of the control population, were calculated. ROC curves of the indices and GHT were constructed. Agreement between the indices was explored with a proportional Venn diagram and 3 × 3 contingency tables. Cases of disagreement between the indices were reviewed.
RESULTS: The area under the ROC curves were HMD=0.745 (95% confidence interval (CI) 0.705-0.786), HSD=0.864 (95% CI 0.833-0.894), NP=0.863 (95% CI 0.832-0.893) and GHT=0.792 (95% CI 0.754-0.829). The Venn diagram and contingency tables highlighted the good agreement between HSD, NP and GHT. Agreement was 78% (HSD vs. GHT) and 82% (NP vs. GHT) in the control sample and 70% (HSD vs. GHT) and 71% (NP vs. GHT) in the POAG sample. Five cases are presented where disagreement existed between the indices.
CONCLUSIONS: The new HSD and NP asymmetry indices perform better than GHT in differentiating between normal and POAG eyes in this data set. GHT can fail to detect significant asymmetry, detected by HSD and NP, when an early defect crosses sector boundaries.

Entities:  

Mesh:

Year:  2015        PMID: 26315707      PMCID: PMC4815696          DOI: 10.1038/eye.2015.165

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  17 in total

1.  The Collaborative Initial Glaucoma Treatment Study: study design, methods, and baseline characteristics of enrolled patients.

Authors:  D C Musch; P R Lichter; K E Guire; C L Standardi
Journal:  Ophthalmology       Date:  1999-04       Impact factor: 12.079

2.  Enhanced Glaucoma Staging System (GSS 2) for classifying functional damage in glaucoma.

Authors:  Paolo Brusini; Stefano Filacorda
Journal:  J Glaucoma       Date:  2006-02       Impact factor: 2.503

3.  Glaucoma Hemifield Test. Automated visual field evaluation.

Authors:  P Asman; A Heijl
Journal:  Arch Ophthalmol       Date:  1992-06

4.  Evaluation of methods for automated Hemifield analysis in perimetry.

Authors:  P Asman; A Heijl
Journal:  Arch Ophthalmol       Date:  1992-06

5.  The concept of visual field indices.

Authors:  J Flammer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1986       Impact factor: 3.117

6.  Screening for glaucomatous visual field loss with automated threshold perimetry.

Authors:  A Sommer; C Enger; K Witt
Journal:  Am J Ophthalmol       Date:  1987-05-15       Impact factor: 5.258

7.  Analytic approaches to the interpretation of automated threshold perimetric data for the diagnosis of early glaucoma.

Authors:  A Sommer; C Duggan; C Auer; H Abbey
Journal:  Trans Am Ophthalmol Soc       Date:  1985

8.  The mode of progression of visual field defects in glaucoma.

Authors:  F S Mikelberg; S M Drance
Journal:  Am J Ophthalmol       Date:  1984-10-15       Impact factor: 5.258

9.  Automated differential threshold perimetry for detecting glaucomatous visual field loss.

Authors:  C Duggan; A Sommer; C Auer; K Burkhard
Journal:  Am J Ophthalmol       Date:  1985-09-15       Impact factor: 5.258

10.  Repeatability of the Glaucoma Hemifield Test in automated perimetry.

Authors:  J Katz; H A Quigley; A Sommer
Journal:  Invest Ophthalmol Vis Sci       Date:  1995-07       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.